Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial
Author:
Affiliation:
1. Pfizer Inc; Groton CT USA
2. Pfizer Inc; Collegeville PA USA
3. Pfizer Inc; Sandwich UK
4. Projections Research Inc; Phoenixville PA USA
Funder
Pfizer
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13523/fullpdf
Reference19 articles.
1. Inflammatory bowel disease: cause and immunobiology;Baumgart;Lancet,2007
2. Inflammatory bowel disease: clinical aspects and established and evolving therapies;Baumgart;Lancet,2007
3. Course of ulcerative colitis: analysis of changes in disease activity over years;Langholz;Gastroenterology,1994
4. Review article: remission rates achievable by current therapies for inflammatory bowel disease;Peyrin-Biroulet;Aliment Pharmacol Ther,2011
5. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review;Gisbert;Am J Gastroenterol,2009
Cited by 31 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study;Intestinal Research;2024-07-31
2. Approach to loss of response to advanced therapies in inflammatory bowel disease;World Journal of Gastroenterology;2024-06-14
3. Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme;Journal of Crohn's and Colitis;2024-04-13
4. Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis;The Lancet Gastroenterology & Hepatology;2023-08
5. Selective Inhibitors of Janus Kinase 3 Modify Responses to Lipopolysaccharides by Increasing the Interleukin-10-to-Tumor Necrosis Factor α Ratio;ACS Pharmacology & Translational Science;2023-05-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3